These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 15828854)

  • 1. Pharmacokinetic/pharmacodynamic and time-to-event models of ribavirin-induced anaemia in chronic hepatitis C.
    Tod M; Farcy-Afif M; Stocco J; Boyer N; Bouton V; Sinègre M; Marcellin P
    Clin Pharmacokinet; 2005; 44(4):417-28. PubMed ID: 15828854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suboptimal endogenous erythropoietin response in chronic hepatitis C patients during ribavirin and PEG interferon treatment.
    Van Vlerken LG; Van Soest H; Janssen MP; Boland GJ; Drenth JP; Burger DM; Siersema PD; Van Erpecum KJ
    Eur J Gastroenterol Hepatol; 2010 Nov; 22(11):1308-15. PubMed ID: 20729740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A formula to estimate the optimal dosage of ribavirin for the treatment of chronic hepatitis C: influence of ITPA polymorphisms.
    Krishnan SM; Dixit NM
    Antivir Ther; 2012; 17(8):1581-92. PubMed ID: 22809728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SLC29A1 polymorphism and prediction of anaemia severity in patients with chronic hepatitis C receiving triple therapy with telaprevir.
    Milazzo L; Peri AM; Mazzali C; Magni C; Calvi E; De Nicolò A; Clementi E; Cheli S; D'Avolio A; Antinori S; Falvella FS
    J Antimicrob Chemother; 2015 Apr; 70(4):1155-60. PubMed ID: 25583751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evidence-based therapeutic drug monitoring for ribavirine].
    Solas C; Paré M; Quaranta S; Stanke-Labesque F;
    Therapie; 2011; 66(3):221-30. PubMed ID: 21819806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial.
    Liu CH; Liu CJ; Huang CF; Lin JW; Dai CY; Liang CC; Huang JF; Hung PH; Tsai HB; Tsai MK; Lee CY; Chen SI; Yang SS; Su TH; Yang HC; Chen PJ; Chen DS; Chuang WL; Yu ML; Kao JH
    Gut; 2015 Feb; 64(2):303-11. PubMed ID: 24747867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin.
    Snoeck E; Wade JR; Duff F; Lamb M; Jorga K
    Br J Clin Pharmacol; 2006 Dec; 62(6):699-709. PubMed ID: 17118125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin.
    Kurosaki M; Tanaka Y; Tanaka K; Suzuki Y; Hoshioka Y; Tamaki N; Kato T; Yasui Y; Hosokawa T; Ueda K; Tsuchiya K; Kuzuya T; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Matsuura K; Sugauchi F; Enomoto N; Nishida N; Tokunaga K; Mizokami M; Izumi N
    Antivir Ther; 2011; 16(5):685-94. PubMed ID: 21817190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin.
    Núñez M; Ocampo A; Aguirrebengoa K; Cervantes M; Pascual A; Echeverria S; Asensi V; Barreiro P; Garcia-Samaniego J; Soriano V;
    J Viral Hepat; 2008 May; 15(5):363-9. PubMed ID: 18179454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia.
    Lindahl K; Schvarcz R; Bruchfeld A; Ståhle L
    J Viral Hepat; 2004 Jan; 11(1):84-7. PubMed ID: 14738562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal dysfunction associated with telaprevir-containing triple therapy for chronic hepatitis C: is early prediction possible?
    Rémy AJ; Lesgourgues B; Nalet B; Causse X; Henrion J; Denis J; Arotçarena R; Hagège H; Pariente A;
    Eur J Gastroenterol Hepatol; 2014 Sep; 26(9):996-1002. PubMed ID: 25072384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy.
    Clark PJ; Aghemo A; Degasperi E; Galmozzi E; Urban TJ; Vock DM; Patel K; Thompson AJ; Rumi MG; D'Ambrosio R; Muir AJ; Colombo M
    J Viral Hepat; 2013 Dec; 20(12):858-66. PubMed ID: 24304455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ribavirin suppresses erythroid differentiation and proliferation in chronic hepatitis C patients.
    Ronzoni L; Aghemo A; Rumi MG; Prati G; Colancecco A; Porretti L; Monico S; Colombo M; Cappellini MD
    J Viral Hepat; 2014 Jun; 21(6):416-23. PubMed ID: 24750239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients.
    Mira JA; López-Cortés LF; Merino D; Arizcorreta-Yarza A; Rivero A; Collado A; Ríos-Villegas MJ; González-Serrano M; Torres-Tortoso M; Macías J; Valera-Bestard B; Fernández-Fuertes E; Girón-González JA; Lozano F; Pineda JA;
    Antivir Ther; 2007; 12(8):1225-35. PubMed ID: 18240862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons.
    Alvarez D; Dieterich DT; Brau N; Moorehead L; Ball L; Sulkowski MS
    J Viral Hepat; 2006 Oct; 13(10):683-9. PubMed ID: 16970600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of cirrhosis, interferon and azathioprine on adverse events in patients with chronic hepatitis C treated with ribavirin.
    Thevenot T; Mathurin P; Moussalli J; Perrin M; Plassart F; Blot C; Opolon P; Poynard T
    J Viral Hepat; 1997 Jul; 4(4):243-53. PubMed ID: 9278222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for anaemia in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with interferon plus ribavirin.
    Bani-Sadr F; Goderel I; Penalba C; Billaud E; Doll J; Welker Y; Cacoub P; Pol S; Perronne C; Carrat F;
    J Viral Hepat; 2007 Sep; 14(9):639-44. PubMed ID: 17697016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Normal erythropoietin response in chronic hepatitis C patients with ribavirin-induced anaemia.
    Durante Mangoni E; Marrone A; Saviano D; Del Vecchio C; Utili R; Ruggiero G
    Antivir Ther; 2003 Feb; 8(1):57-63. PubMed ID: 12713065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial.
    Liu CH; Huang CF; Liu CJ; Dai CY; Liang CC; Huang JF; Hung PH; Tsai HB; Tsai MK; Chen SI; Lin JW; Yang SS; Su TH; Yang HC; Chen PJ; Chen DS; Chuang WL; Yu ML; Kao JH
    Ann Intern Med; 2013 Dec; 159(11):729-38. PubMed ID: 24297189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection.
    Sulkowski MS; Wasserman R; Brooks L; Ball L; Gish R
    J Viral Hepat; 2004 May; 11(3):243-50. PubMed ID: 15117326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.